【摘要】  　　目的：研究玻璃体腔内单次注射曲安奈德（TA）治疗非增殖性弥漫性糖尿病黄斑水肿(DME)的疗效及安全性。方法：玻璃体腔内单次注射TA 4mg/0.1mL治疗非增殖性弥漫性DME25眼，观察治疗前后视力、黄斑区视网膜神经感觉层厚度、眼压的变化以及并发症的发生情况。结果：治疗后1mo与治疗前相比，视力提高显著 （P =0.0004）；治疗后3mo与治疗后1mo比较，视力显著提高（P =0.0006）；治疗后6mo与治疗前相比，视力无显著性差异（P =0.0935）。治疗后1mo黄斑区周围1.00mm范围内视网膜神经感觉层厚度与治疗前相比，显著降低（P =0.0000）；治疗后3mo与治疗后1mo相比，显著降低（P =0.0303）；治疗后6mo后与治疗后3mo相比，显著升高(P =0.0000),但与治疗后1mo相比,仍显著降低(P = 0.0000)。治疗后10,40min眼压与治疗前相比显著升高(P = 0.0000)；而治疗后1d与治疗前相比无显著性差异（P = 0.1766）。 结论：玻璃体腔内单次注射TA 4mg/0.1mL治疗非增殖性弥漫性DME，短期疗效确实，可以明显减轻水肿、改善患者视功能，安全性较高。

【关键词】  曲安奈德　糖尿病视网膜病变　黄斑水肿

　　Clinical therapeutic effects of intracavity injection of triamcinolone acetonide for diffuse diabetic macular edema

      Abstract AIM: To observe clinical therapeutic effects and safety of single intracavity injection of triamcinolone acetonide(TA) for nonproliferative diffuse diabetic macular edema(DME). METHODS: Twenty-five eyes with nonproliferative diffuse DME received single injection of 4mg/0.1mL TA into vitreous. Mean best-corrected visual acuity, thickness of the neurosensory retina, intraocular pressure (IOP) and adverse reaction were observed and analyzed.&n……